Op-T LLC
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus (NCT06964087) | Op-T LLC | 2026-04-10 |
| OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis (NCT06669403) | Op-T LLC | 2025-12-01 |
| OPT101 in Type 1 Diabetes Patients (NCT05428943) | Op-T LLC | 2022-09-27 |
| 1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide. (NCT04589403) | Op-T LLC | 2021-02-18 |
Track Op-T LLC automatically
Every clearance here is in the API, with alerts when new ones post.